Company Overview and News

Deep Yellow has drill bit spinning at Reptile uranium target

A 10,000-metre reverse circulation program will assess circa 40 kilometres of the 100 kilometres of highly prospective paleochannel system.
Upvote Downvote

Deep Yellow to explore new uranium targets at Namaqua in 2018

Deep Yellow Limited (ASX:DYL) has completed a 7490 metre scout drilling program at its Nova Energy Joint Venture project, Namibia (Nova JV).
Upvote Downvote

Deep Yellow raises $15.1M to advance uranium projects in Namibia

Deep Yellow (ASX:DYL) is well funded to continue its uranium exploration activities in Namibia after successfully closing a $15.1 million entitlement issue.
Upvote Downvote

Paladin Energy's (PALAF) CEO Alexander Alan Molyneux on Q2 2017 Results - Earnings Call Transcript

2017-02-15 seekingalpha
Ladies and gentlemen thank you for standing by and welcome to the Paladin Energy December Half-Year Results Conference Call and Investor Update. At this time, all participants are in a listen-only mode. There will be a presentation followed by a question-and-answer session now. [Operator Instructions] I must advice you that this conference is being recorded today, Wednesday, 15 February, 2017.
Upvote Downvote

Paladin Energy Limited: Quarterly Activities Report for the Period Ending 31 December 2016

2017-01-18 marketwired
PERTH, WESTERN AUSTRALIA--(Marketwired - January 18, 2017) - Paladin Energy Ltd ("Paladin" or "the Company") (TSX: PDN)(ASX: PDN) announces the release of its Quarterly Activities Report for the period ended 31 December 2016.
Upvote Downvote

Paladin Energy Could Be Forced Into Bankruptcy By Electricité de France's Request For Collateral

2017-01-03 seekingalpha
It looks like the company could come up with enough cash to repay the April 2017 bond, but a recent letter from offtake partner EDF could derail everything.
Upvote Downvote

Paladin Energy Limited: Sale of Deep Yellow Shareholding

2016-12-14 marketwired
PERTH, WESTERN AUSTRALIA--(Marketwired - December 14, 2016) - Paladin Energy Ltd (Paladin or the Company) (ASX: PDN) (TSX: PDN) wishes to advise it has sold its entire shareholding in Deep Yellow Limited. The sale price of A$0.01 per share will translate to a receipt of approximately A$2.6M.
Upvote Downvote

Paladin raises $5.1m from asset sales

Paladin Energy has offloaded its entire shareholding in Deep Yellow, taking advantage of a share price spike after the uranium miner’s former managing director John Borshoff joined the junior explorer.
Upvote Downvote

Deep Yellow Ltd has a new substantial shareholder

Deep Yellow Ltd (ASX:DYL) has received a notice of initial substantial holder from Exploration Capital Partners 2014 Limited Partnership..
Upvote Downvote

Deep Yellow Ltd to be run by uranium industry legend

Deep Yellow Ltd (ASX:DYL) is set to benefit from the leadership of new managing director and CEO, John Borshoff.
Upvote Downvote

Deep Yellow tops ASX % Gainers intra-day

Proactive Investors is a global leader in financial news, media, research and events focusing on emerging growth companies across four continents.
Upvote Downvote

Borshoff leads another uranium play

Former Paladin Energy boss John Borshoff has emerged as chief executive of another local uranium-focused company, Deep Yellow.
Upvote Downvote

Deep Yellow Ltd moves towards finalising capital raising

Deep Yellow Ltd (ASX:DYL) is currently finalising a capital raising, and the ASX has granted the company more time with a voluntary suspension, following a trading halt.
Upvote Downvote

Deep Yellow to raise funds for uranium in Namibia

The halt will remain in place until the opening of trade on Friday 21st October 2016, or earlier if an announcement is made to the market.
Upvote Downvote

Final Results for the Year Ended 30 June 2016

2016-10-14 londonstockexchange
·      Tschudi ramp-up completed in the year, achieving Commercial Production from 1st October 2015 and achieving design nameplate production rate in December 2015.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...